ITGAM and neoplasm: We found that metronomic CPA suppressed CD11b+/Gr1+ MDSC reservoirs in bone marrow and spleen, consistent with reports for metronomic schedules of other cancer chemotherapeutic drugs [20,21], but did not significantly increase tumor-associated MDSCs, which have the ability to counter innate immunity by suppressing NK cell activity [22].